These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 20191897)

  • 21. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Serum lipid-associated sialic acid (LSA) in diagnosing and monitoring ovarian cancer].
    Yue K; Bian M; Zhu D; Liu W; Siu S
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1995 Apr; 17(2):128-32. PubMed ID: 7656393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tissue polypeptide specific antigen (TPS) and carbohydrate antigen 125 (CA-125) in the early prediction of recurrent ovarian cancer.
    Yeh LS; Hung YC; Kao A; Lin CC; Lee CC
    Anticancer Res; 2002; 22(6B):3669-71. PubMed ID: 12552974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [15 years CA-125 antigen: usefulness and limits. Apropos of 3 clinical cases].
    Petignat P; Vajda D; Obrist R
    Praxis (Bern 1994); 1998 Nov; 87(47):1602-5. PubMed ID: 9865132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A retrospective study of preoperative CA 125 levels in 82 patients with ovarian cancer.
    Rossi AC; Di Vagno G; Cormio G; Cazzolla A; Stefanelli S; D'Elia E; Selvaggi L
    Arch Gynecol Obstet; 2004 May; 269(4):263-5. PubMed ID: 14745561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers for the early detection of cancer: an inflammatory concept.
    Roy HK; Khandekar JD
    Arch Intern Med; 2007 Sep; 167(17):1822-4. PubMed ID: 17893302
    [No Abstract]   [Full Text] [Related]  

  • 27. Monitoring ovarian cancer: CA125 trial stirs controversy.
    Chitale R
    J Natl Cancer Inst; 2009 Sep; 101(18):1233-5. PubMed ID: 19738165
    [No Abstract]   [Full Text] [Related]  

  • 28. Peritoneal fluid lactate dehydrogenase in ovarian cancer.
    Schneider D; Halperin R; Langer R; Bukovsky I; Herman A
    Gynecol Oncol; 1997 Sep; 66(3):399-404. PubMed ID: 9299252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The value of cancer antigen 125 (CA 125) during treatment and follow-up of patients with ovarian cancer.
    de Bruijn HW; van der Zee AG; Aalders JG
    Curr Opin Obstet Gynecol; 1997 Feb; 9(1):8-13. PubMed ID: 9090475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic, biochemical, and multimodal approaches to screening for ovarian cancer.
    Jacobs I
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S22-7. PubMed ID: 7835805
    [No Abstract]   [Full Text] [Related]  

  • 31. [Epithelial ovarian cancer--preoperative assessment of Ca 125 levels as an independent prognostic factor].
    Ivanov S; Ivanov S
    Akush Ginekol (Sofiia); 2003; 42(3):16-9. PubMed ID: 12858485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The myth of measurable disease in ovarian cancer: revisited.
    Markman M
    Cancer Invest; 2009 Jan; 27(1):11-2. PubMed ID: 19160094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [-CA-125 antigen as a prognostic factor for survival in patients with epithelial ovarian carcinoma of FIGO stage I--preliminary results-].
    Nagele E; Kurz C; Speiser P; Vavra N; Sevelda P
    Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):79-82. PubMed ID: 8647363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms.
    HarĊ‚ozinska A; Sedlaczek P; Van Dalen A; Rozdolski K; Einarsson R
    Anticancer Res; 1997; 17(6D):4473-8. PubMed ID: 9494553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
    Hermsen BB; von Mensdorff-Pouilly S; Berkhof J; van Diest PJ; Gille JJ; Menko FH; Blankenstein MA; Kenemans P; Verheijen RH
    J Clin Oncol; 2007 Apr; 25(11):1383-9. PubMed ID: 17416858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New prospects in the combined use of tumor markers in epithelial neoplasms of the ovary].
    Indraccolo SR; Cecchi A; Thodos A; Brandi S; Carta G
    Ann Ostet Ginecol Med Perinat; 1991; 112(1):36-40. PubMed ID: 1929097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Application of multi-tumor markers in ovarian carcinoma].
    Feng J; Qian H; Tian Y
    Zhonghua Fu Chan Ke Za Zhi; 1998 May; 33(5):284-6. PubMed ID: 10682440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measurement of serum CA 125 in ovarian cancers.
    Yuan CC; Ng HT; Yeh SH; Jeng FS; Chen SL; Tsai LC
    Zhonghua Yi Xue Za Zhi (Taipei); 1987 Mar; 39(3):153-60. PubMed ID: 3484240
    [No Abstract]   [Full Text] [Related]  

  • 39. Preoperative CA-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer.
    Gemer O; Segal S; Kopmar A
    Acta Obstet Gynecol Scand; 2001 Jun; 80(6):583-5. PubMed ID: 11380298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress report on ovarian cancer screening. Scientists are making headway in detecting ovarian cancer at an earlier stage.
    Harv Womens Health Watch; 2010 Apr; 17(8):1-3. PubMed ID: 20506601
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.